Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 12901560)

1.

Phagocytosis of synthetic particulate vaccine delivery systems to program dendritic cells.

Thiele L, Merkle HP, Walter E.

Expert Rev Vaccines. 2002 Aug;1(2):215-26. Review.

PMID:
12901560
2.

Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines.

Zupancic E, Peres C, Matos AI, Lopes J, Moreira JN, Gaspar RS, Florindo HF.

Curr Top Med Chem. 2015 Jul 1. [Epub ahead of print]

PMID:
26126909
3.

Influence of particle size, an elongated particle geometry, and adjuvants on dendritic cell activation.

Mathaes R, Winter G, Siahaan TJ, Besheer A, Engert J.

Eur J Pharm Biopharm. 2015 Jun 26. pii: S0939-6411(15)00275-1. doi: 10.1016/j.ejpb.2015.06.015. [Epub ahead of print]

PMID:
26118563
4.

Carbon nanotubes as vaccine scaffolds.

Scheinberg DA, McDevitt MR, Dao T, Mulvey JJ, Feinberg E, Alidori S.

Adv Drug Deliv Rev. 2013 Dec;65(15):2016-22. doi: 10.1016/j.addr.2013.07.013. Epub 2013 Jul 27. Review.

5.

An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines.

Salvador A, Igartua M, Hernández RM, Pedraz JL.

J Drug Deliv. 2011;2011:181646. doi: 10.1155/2011/181646. Epub 2011 Jun 15.

6.

Designing oral vaccines targeting intestinal dendritic cells.

Devriendt B, De Geest BG, Cox E.

Expert Opin Drug Deliv. 2011 Apr;8(4):467-83. doi: 10.1517/17425247.2011.561312. Epub 2011 Mar 5. Review.

PMID:
21375470
7.

Nasal vaccine innovation.

Jabbal-Gill I.

J Drug Target. 2010 Dec;18(10):771-86. doi: 10.3109/1061186X.2010.523790. Review.

PMID:
21047271
8.

The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants.

Harris J, Sharp FA, Lavelle EC.

Eur J Immunol. 2010 Mar;40(3):634-8. doi: 10.1002/eji.200940172. Review.

PMID:
20201019
9.

Strategies for optimizing targeting and delivery of mucosal HIV vaccines.

Ahlers JD, Belyakov IM.

Eur J Immunol. 2009 Oct;39(10):2657-69. doi: 10.1002/eji.200939269. Review.

PMID:
19609978
10.

Immunology of TLR-independent vaccine adjuvants.

De Gregorio E, D'Oro U, Wack A.

Curr Opin Immunol. 2009 Jun;21(3):339-45. doi: 10.1016/j.coi.2009.05.003. Epub 2009 Jun 1. Review.

PMID:
19493664
11.

A high-throughput microparticle microarray platform for dendritic cell-targeting vaccines.

Acharya AP, Clare-Salzler MJ, Keselowsky BG.

Biomaterials. 2009 Sep;30(25):4168-77. doi: 10.1016/j.biomaterials.2009.04.032. Epub 2009 May 28.

PMID:
19477505
12.

Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination.

Aline F, Brand D, Pierre J, Roingeard P, Séverine M, Verrier B, Dimier-Poisson I.

Vaccine. 2009 Aug 20;27(38):5284-91. doi: 10.1016/j.vaccine.2009.05.028. Epub 2009 May 29.

PMID:
19450633
13.

Enhanced CTL response by controlled intracellular trafficking of antigen in dendritic cells following DNA vaccination.

Isaji K, Kawase A, Matono M, Guan X, Nishikawa M, Takakura Y.

J Control Release. 2009 May 5;135(3):227-33. doi: 10.1016/j.jconrel.2009.01.026. Epub 2009 Feb 7.

PMID:
19331843
14.

Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.

Jasani B, Navabi H, Adams M.

Vaccine. 2009 May 26;27(25-26):3401-4. doi: 10.1016/j.vaccine.2009.01.071. Epub 2009 Feb 5.

PMID:
19200817
15.

Biomaterials as vaccine adjuvants.

Jones KS.

Biotechnol Prog. 2008 Jul-Aug;24(4):807-14. doi: 10.1002/btpr.10. Review.

PMID:
19194892
16.

ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.

Schnurr M, Orban M, Robson NC, Shin A, Braley H, Airey D, Cebon J, Maraskovsky E, Endres S.

J Immunol. 2009 Feb 1;182(3):1253-9. Erratum in: J Immunol. 2009 Apr 15;182(8):5152.

17.

Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome.

Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, Singh M, O'Hagan DT, Pétrilli V, Tschopp J, O'Neill LA, Lavelle EC.

Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):870-5. doi: 10.1073/pnas.0804897106. Epub 2009 Jan 12.

18.

Recent developments in particulate-based vaccines.

Perrie Y, Kirby D, Bramwell VW, Mohammed AR.

Recent Pat Drug Deliv Formul. 2007;1(2):117-29. Review.

PMID:
19075879
19.

Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.

van de Loosdrecht AA, van den Ancker W, Houtenbos I, Ossenkoppele GJ, Westers TM.

Handb Exp Pharmacol. 2009;(188):319-48. doi: 10.1007/978-3-540-71029-5_15. Review.

PMID:
19031033
20.

Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors.

Benko S, Magyarics Z, Szabó A, Rajnavölgyi E.

Biol Chem. 2008 May;389(5):469-85. Review.

PMID:
18953714
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk